Health X Platform Limited

Healthcare — Pharmaceutical Retailers · NSE

₹282.20−₹1.30 (−0.46%)

DalalBaazaar Score

39 / 100

🔴 Weak

Verdict

CAUTION

Risk

Very High

Driven by high debt relative to equity, negative free cash flow, the company is currently loss-making.

In simple words: The company is currently losing money, though profits are falling even as sales grow. Debt is the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:03 pm

Understanding the Business

Company site ↗

The 60-second version of Health X Platform Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Health X Platform Limited operates a digital network of healthcare and portfolio management services in India. The company operates through the Financial Services, Healthcare Network, and Others segments.

IndustryPharmaceutical Retailers

SectorHealthcare

Employees2,760

Annual revenue₹1,308 Cr

How does it make money?

Turns over ₹1,308 Cr a year. Of every ₹100 of sales, about ₹0 reaches shareholders as profit, with ₹-2 left at the operating level before interest, tax and depreciation. Each of its 2,760 employees supports ₹47.4 lakh of revenue a year, the signature of a people-led business.

Revenue / employee₹47.4 lakh

Who are its competitors?

The closest listed comparisons in its industry are SUN PHARMACEUTICAL IND L, DR. REDDY S LABORATORIES, CIPLA LTD, DIVI S LABORATORIES LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Little sign of one

Returns on capital of -0.2% are at or below what the capital likely costs. That is the financial pattern of a business competing largely on price, where advantage has to come from execution rather than position.

Peer median ROE14.5%

What has been driving growth?

Profit has moved mainly because margins changed, not because the business sold much more. Over 3 years revenue moved +26% while net margin moved -101% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+26%

Margin effect-101%

DalalBaazaar Score

39/ 100

Weak

Weighted across six categories. Every point is explained below.

✗ Debt/Equity of 3.35x is high — earnings must service borrowings before shareholders see anything
✓ Current ratio of 2.46 — short-term bills are well covered
✗ Free cash flow is negative — growth is being funded by borrowing or fresh equity
✗ Interest cover of only -2.2x — little room if profits dip
✗ Debt has grown 40.1% a year — worth checking what it bought

Quality vs. Valuation

Company Quality

37/ 100

Weak

How good the business is, ignoring the share price entirely.

Valuation

36/ 100

Expensive

What you are being asked to pay, ignoring how good the business is.

Weak on business quality and not cheap enough to compensate.

vs. its own history

Not enough price and earnings history

vs. sector peers

Not enough peers with a usable P/E

vs. generic bands

N/A

No P/E — the company is lossmaking

EV/EBITDA

—

PEG

—

What's Good / What's Bad

🟢 What's Going Well3

Margins are improving
EBITDA margin is up from -10.4% to -2.1% over 3 years.
Return on equity is rising
ROE has improved from -9.6% to 0.2%.
Return on capital is rising
ROCE has improved from -10.9% to -0.2%.

🔴 What Needs Attention0

Nothing stands out as clearly deteriorating on the years of data available.

Red Flags

5 items require attention · 4 high · 1 watch

🔴Debt has risen sharplyFinancial
Total debt is up 175% over 3 years, from ₹9 Cr to ₹26 Cr.
🔴High leverageFinancial
Debt/Equity of 3.35x — earnings must service borrowings before shareholders see anything.
🔴Thin interest coverageFinancial
Operating profit covers interest only -2.2x — little room if earnings dip.
🔴Profit up while operating cash flow fallsFinancial
Reported profit rose but cash generated by operations declined — worth checking whether earnings are being supported by non-cash items or working capital.
🟡Free cash flow is negativeFinancial
Free cash flow was -₹89 Cr in the latest year.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Margin expansion has further to run
EBITDA margin has risen from -10.4% to -2.1%. If that holds, profit compounds faster than sales and today's multiple looks cheaper in hindsight than it does now.

🔴 Bear CaseWhat could go wrong?

Leverage amplifies any setback
Debt/Equity of 3.35x. Interest is payable whether or not the business has a good year.
Growth barely outpaces inflation
Revenue compounding at 8.0% a year is close to the rate prices rise, so the business is gaining little ground in real terms. That leaves the share price dependent on a re-rating rather than on earnings growth.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.
Several serious flags at once
4 high-severity checks triggered. Individually each has an explanation; together they raise the chance that something structural is wrong rather than a one-off.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1EBITDA margin holds above -4%✓ -2.1%
Two points below today's level — enough room for noise, tight enough to catch real compression.
2Free cash flow remains positive✗ -₹89 Cr
Profit that never becomes cash eventually stops being profit.
3Interest cover stays above 3x✗ -2.2x
How much operating profit can fall before interest stops being comfortably covered.
4Revenue growth stays above 6% a year✓ 8.0% CAGR
Latest reported year was 42.0%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
5ROCE stays above 8%✗ -0.2%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

4 / 11 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✗ Strong return on capital employed (ROCE ≥ 15%)
✗ Healthy net margin (≥ 10%)
✗ Generates positive free cash flow
✗ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✗ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

2 good · 2 neutral · 7 weak

Market Cap

₹898 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

Not meaningful

Loss-making

Earnings are negative, so a P/E multiple can't be read here

P/B Ratio

1.40x

Reasonable

Reasonable against the company's book value

EPS (TTM)

₹-6.34

Loss-making

Negative earnings per share — the business is losing money

ROE

0.2%

Weak

Weak capital efficiency

ROCE

-0.2%

Weak

Low return on total capital employed

Debt/Equity

3.35x

High

High leverage

Revenue Growth (YoY)

42.0%

Healthy

Healthy top-line growth

Profit Growth (YoY)

-89.4%

Falling

Profits are shrinking

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

-₹89 Cr

Cash burning

Spending more cash than the operations bring in

More Metrics

Operating Margin

0.6%

Weak

Thin margins leave little room for error

Net Margin

-1.3%

Weak

Very little revenue reaches the bottom line

Current Ratio

2.46

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

0.39

Defensive

Steadier than the market

52W Range Position

27%

Mid-range

Technical Snapshot

SMA 20 / SMA 50

286.9 / 294.4

Bearish alignment (short < long)

Price vs SMA 200

Below

Long-term downtrend

RSI (14)

45.4

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹1,038 Cr	₹1,356 Cr	₹1,090 Cr	₹1,308 Cr	+8.0%
EBITDA	-₹108 Cr	-₹72 Cr	-₹35 Cr	-₹27 Cr	—
EBITDA Margin	-10.4%	-5.3%	-3.2%	-2.1%	—
PAT (Net Profit)	-₹72 Cr	₹9 Cr	-₹91 Cr	₹1 Cr	—
EPS	₹-22.7	₹2.79	₹-28.66	₹0.37	—
ROE	-9.6%	1.2%	-13.6%	0.2%	—
ROCE	-10.9%	-2.7%	-23.2%	-0.2%	—
Total Debt	₹9 Cr	₹4 Cr	₹1 Cr	₹26 Cr	+40.1%
Free Cash Flow	-₹131 Cr	₹22 Cr	-₹28 Cr	-₹89 Cr	—

🟢 Revenue has grown at 8.0% a year over 3 years.

🟢 EBITDA Margin has risen from -10.4% to -2.1% over 3 years (+8.4 pts).

🟢 PAT (Net Profit) has turned positive, from -₹72 Cr to ₹1 Cr.

🟢 EPS has turned positive, from ₹-22.7 to ₹0.37.

🟢 ROE has risen from -9.6% to 0.2% over 3 years (+9.8 pts).

🟢 ROCE has risen from -10.9% to -0.2% over 3 years (+10.7 pts).

🔴 Total Debt has grown at 40.1% a year over 3 years.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹936 Cr

Total Liabilities

₹170 Cr

Cash & Equivalents

₹30 Cr

Operating Cash Flow

-₹74 Cr

Capex

-₹15 Cr

Shareholding (proxy)

Institutional Holding

1.2%

Insider Holding

79.9%

Corporate Actions

Ex-Dividend Date

23 Jul 2012

Peer Comparison

Company	P/E	ROE
SUN PHARMACEUTICAL IND L	34.9x	14.5%
DR. REDDY S LABORATORIES	31.0x	8.8%
CIPLA LTD	31.8x	9.8%
DIVI S LABORATORIES LTD	83.0x	17.5%

Recent News

3 mixed3 general

Health X Platform (NSEI:HEALTHX) - Stock Analysis

Simply Wall Street, 15 Oct

Health X Platform Q1 Results: Earnings call scheduled for Aug 11

scanx.trade, 05 AugResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Sastasundar Ventures Share Price Rises 14.53% Today

Univest, 08 OctPrice move

🟡Mixed / dependsA price move, which is not by itself a change in the business. Worth finding the cause before reading it as either good or bad.

Health X Platform Ltd Forms Death Cross Signalling Bearish Trend

MarketsMojo, 13 OctAnalyst view

🟡Mixed / dependsBroker commentary — an opinion about the price rather than new information about the business.

M3 (TSE:2413) Draws Activist Attention, Is The Stock Fully Priced?

Simply Wall Street, 18 Oct

Health X Platform wins service tax appeal, avoids ₹65.19 lakh liability

scanx.trade, 03 Aug

Watch Items

Cross-check against the company's latest quarterly filing / investor presentation before acting.

DalalBaazaar Thesis

MiddlingValuation

WeakBusiness Quality · Financial Health · Growth · Profitability · Risk

Points for each in the Score ↑

Weak on the fundamentals

Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation. 4 high-severity red flags sit above this conclusion and should be read first.

3 of 5 tripwires tripped — Free cash flow remains positive; Interest cover stays above 3x; ROCE stays above 8% · see Key things to watch ↑